Update on Controlled Substances and Telehealth Prescribing
On June 14th the U.S. Drug Enforcement Agency (DEA) submitted their long-awaited final rule for telehealth prescribing of controlled substances to the White House Office of Management and Budget (OMB) for a final rule before publication. The rules are expected to be published sometime prior to December 2024. As previously reported, in May 2023 the DEA had temporarily extended the COVID-19 telemedicine flexibilities for prescribing controlled substances. By way of background, The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires prescribers to conduct an in-person examination to evaluate each new patient at least once before prescribing a controlled substance. After...
Revised Regulation: DEA-Registered Pharmacies can Transfer Electronic Prescriptions at a Patient’s Request
On September 1st, 2023, the DEA released a revised regulation allowing pharmacies to transfer electronic prescriptions for controlled substances to another pharmacy at the patient's request. This can be very helpful given some of the medication shortages patients have experienced over the last year. The new rule allows for a one-time transfer of electronic prescriptions for Schedule II-V controlled substances to another pharmacy without having to involve the prescribing provider. Patients will no longer need to call their provider and ask for the prescription to be sent to a different pharmacy. Any authorized refills included on a prescription for a...
DEA Extends COVID Telemedicine Prescribing Rules for Controlled Substances
UPDATE: DEA and HHS Extend Telemedicine Flexibilities through 2024 October 9, 2023 Statement from the DEA on Telemedicine Flexibilities deadline: "We continue to carefully consider the input received and are working to promulgate a final set of telemedicine regulations by the fall of 2024, giving patients and medical practitioners time to plan for, and adapt to, the new rules once issued. Accordingly, DEA, jointly with the Department of Health and Human Services (HHS), has extended current telemedicine flexibilities through December 31, 2024. The full text of the extension, entitled “Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled...
DEA Announces Proposed Telemedicine Rule Change for Controlled Substances
On 2/24/23 the U.S. Drug Enforcement Agency (DEA) announced a proposal for permanent rule changes to the Ryan Haight Act that will allow for the prescription of controlled substances through telemedicine, under certain circumstances, after the federal COVID-19 Public Health Emergency (PHE) expires on May 11, 2023. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires prescribers conduct an in-person examination to evaluate each patient at least once before prescribing a controlled substance, even if a patient has already been taking the medication in question. During the PHE, the in-person requirement was changed to allow prescribers to perform...
As of October 2, 2018, all providers practicing in California must check the Controlled Substance Utilization Review and Evaluation System (CURES) database before prescribing certain medications, including opioid pain medications. Physicians and advanced practice providers who prescribe controlled substances already must be registered with CURES 2.0, according to state law. California Health and Safety Code Section 11165.1 requires health care practitioners authorized to prescribe, order, administer, furnish, or dispense scheduled controlled substances to submit a CURES registration application to the Department of Justice before July 1, 2016, or upon receipt of a DEA registration. Senate Bill 482, which was signed...